Wuhan Nanobody Life Science & Technology Co., Ltd. (referred to as NBLST) specializes in providing clients with high-quality nanobody customization, labeling, and engineering services. The company is also engaged in the R&D, production, and sales of nanobody reagents. NBLST operates a proprietary laboratory spanning 1,400 square meters at the Precision Medicine Industrial Base in Wuhan Bio-City. Furthermore, the company has established alpaca breeding and experimental bases in Zuoling, Wuhan, and Tuanfeng, Huanggang, both compliant with laboratory animal standards. Currently housing over 600 alpacas, these bases enable the direct provision of comprehensive alpaca immunization services to research institutions and antibody drug development enterprises. NBLST has established a robust early-stage antibody drug discovery platform covering the entire process from antigen preparation and specific nanobody screening to preliminary drug development. This platform includes a self-developed high-throughput antibody screening and detection platform. The company employs nanobody technology to engineer membrane protein receptors into nanobodies with specific properties and functions, positioning itself as one of the few enterprises in this field possessing such advanced technology and R&D expertise. It is also among the very few nanobody drug R&D companies in Central China to operate both alpaca breeding and experimental bases. NBLST has received strong support from the Wuhan municipal government and collaborates with multiple research centers and renowned scientists. Committed to building an integrated industry-academia-research experimental public service platform, NBLST aims to provide more professional and cost-effective experimental services for research institutions, pharmaceutical organizations, industrial enterprises, and innovative teams.